These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 38366235)
41. A one-week comfort study of BID-dosed brinzolamide 1%/timolol 0.5% ophthalmic suspension fixed combination compared to BID-dosed dorzolamide 2%/timolol 0.5% ophthalmic solution in patients with open-angle glaucoma or ocular hypertension. Vold SD; Evans RM; Stewart RH; Walters T; Mallick S J Ocul Pharmacol Ther; 2008 Dec; 24(6):601-5. PubMed ID: 19049301 [TBL] [Abstract][Full Text] [Related]
42. Soft Contact Lens with Embedded Microtubes for Sustained and Self-Adaptive Drug Delivery for Glaucoma Treatment. Ding X; Ben-Shlomo G; Que L ACS Appl Mater Interfaces; 2020 Oct; 12(41):45789-45795. PubMed ID: 32960561 [TBL] [Abstract][Full Text] [Related]
43. Brinzolamide/timolol: in open-angle glaucoma and ocular hypertension. Croxtall JD; Scott LJ Drugs Aging; 2009; 26(5):437-46. PubMed ID: 19552495 [TBL] [Abstract][Full Text] [Related]
44. Contrast sensitivity and optical quality of the eye after instillation of timolol maleate gel-forming solution and brinzolamide ophthalmic suspension. Hiraoka T; Daito M; Okamoto F; Kiuchi T; Oshika T Ophthalmology; 2010 Nov; 117(11):2080-7. PubMed ID: 20656353 [TBL] [Abstract][Full Text] [Related]
45. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Sezgin Akçay Bİ; Güney E; Bozkurt KT; Unlü C; Akçali G J Ocul Pharmacol Ther; 2013 Dec; 29(10):882-6. PubMed ID: 24180628 [TBL] [Abstract][Full Text] [Related]
47. Bimatoprost-Loaded Silica Shell-Coated Nanoparticles-Laden Soft Contact Lenses to Manage Glaucoma: In Vitro and In Vivo Studies. Xiaojie H; Fagang J; Jun J; Chunfang W; Chengquan L; Xinghua W AAPS PharmSciTech; 2021 Dec; 23(1):33. PubMed ID: 34950994 [TBL] [Abstract][Full Text] [Related]
48. Additive effects and safety of fixed combination therapy with 1% brinzolamide and 0.5% timolol versus 1% dorzolamide and 0.5% timolol in prostaglandin-treated glaucoma patients. Aihara M; Adachi M; Matsuo H; Togano T; Fukuchi T; Sasaki N; Acta Ophthalmol; 2017 Dec; 95(8):e720-e726. PubMed ID: 28371482 [TBL] [Abstract][Full Text] [Related]
49. Brinzolamide 1%/timolol 0.5%: safety and efficacy of a new fixed-combination IOP-lowering product for glaucoma. Januleviciene I Curr Med Res Opin; 2010 Nov; 26(11):2575-8. PubMed ID: 20868340 [TBL] [Abstract][Full Text] [Related]
50. Brinzolamide Dimethyl Sulfoxide In Situ Gelling Ophthalmic Solution: Formulation Optimisation and In Vitro and In Vivo Evaluation. Bhalerao H; Koteshwara KB; Chandran S AAPS PharmSciTech; 2020 Jan; 21(2):69. PubMed ID: 31950311 [TBL] [Abstract][Full Text] [Related]
51. The effects of topical dorzolamide 2% and brinzolamide 1%, either alone or combined with timolol 0.5%, on intraocular pressure, pupil diameter, and heart rate in healthy cats. Slenter IJM; Djajadiningrat-Laanen SC; Elders DJ; de Gee R; Koele LE; Vermeer LW; Boevé MH Vet Ophthalmol; 2020 Jan; 23(1):16-24. PubMed ID: 31099474 [TBL] [Abstract][Full Text] [Related]
52. Fixed topical combinations in glaucomatous patients and ocular discomfort. Nebbioso M; Evangelista M; Librando A; Di Blasio D; Pescosolido N Expert Opin Pharmacother; 2012 Sep; 13(13):1829-35. PubMed ID: 22770575 [TBL] [Abstract][Full Text] [Related]
53. Cost-minimisation study of dorzolamide versus brinzolamide in the treatment of ocular hypertension and primary open-angle glaucoma: in four European countries. Rouland JF; Le Pen C; Gouveia Pinto C; Berto P; Berdeaux G Pharmacoeconomics; 2003; 21(3):201-13. PubMed ID: 12558470 [TBL] [Abstract][Full Text] [Related]
54. Feasibility of corneal drug delivery of cysteamine using vitamin E modified silicone hydrogel contact lenses. Hsu KH; Fentzke RC; Chauhan A Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):531-40. PubMed ID: 23665502 [TBL] [Abstract][Full Text] [Related]
55. Controlled bimatoprost release from graphene oxide laden contact lenses: In vitro and in vivo studies. Maulvi FA; Soni PD; Patel PJ; Desai AR; Desai DT; Shukla MR; Shah SA; Shah DO; Willcox MDP Colloids Surf B Biointerfaces; 2021 Dec; 208():112096. PubMed ID: 34530331 [TBL] [Abstract][Full Text] [Related]
56. Self-assembled hydrophobic honokiol loaded MPEG-PCL diblock copolymer micelles. Gou M; Zheng X; Men K; Zhang J; Wang B; Lv L; Wang X; Zhao Y; Luo F; Chen L; Zhao X; Wei Y; Qian Z Pharm Res; 2009 Sep; 26(9):2164-73. PubMed ID: 19568695 [TBL] [Abstract][Full Text] [Related]
57. Reduction of intraocular pressure using timolol orally dissolving strips in the treatment of induced primary open-angle glaucoma in rabbits. El-Feky YA; Mostafa DA; Al-Sawahli MM; El-Telbany RFA; Zakaria S; Fayez AM; Ahmed KA; Alolayan EM; El-Telbany DFA J Pharm Pharmacol; 2020 May; 72(5):682-698. PubMed ID: 32170884 [TBL] [Abstract][Full Text] [Related]
58. A triple crosslinked micelle-hydrogel lacrimal implant for localized and prolonged therapy of glaucoma. Zhao J; Xiong J; Ning Y; Zhao J; Wang Z; Long L; He H; Gou J; Yin T; Tang X; Zhang Y Eur J Pharm Biopharm; 2023 Apr; 185():44-54. PubMed ID: 36841507 [TBL] [Abstract][Full Text] [Related]
59. Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%. Kaback M; Scoper SV; Arzeno G; James JE; Hua SY; Salem C; Dickerson JE; Landry TA; Bergamini MV; Ophthalmology; 2008 Oct; 115(10):1728-34, 1734.e1-2. PubMed ID: 18538406 [TBL] [Abstract][Full Text] [Related]
60. Effect of glaucoma medications on 24-hour intraocular pressure-related patterns using a contact lens sensor. Mansouri K; Medeiros FA; Weinreb RN Clin Exp Ophthalmol; 2015 Dec; 43(9):787-95. PubMed ID: 26152693 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]